Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study

被引:0
|
作者
Huang, Zhixin [1 ,2 ,3 ,4 ]
Chen, Dinghang [1 ,2 ,3 ,4 ]
Hong, Zhinuan [1 ,2 ,3 ,4 ]
Kang, Mingqiang [1 ,2 ,3 ,4 ]
机构
[1] Fujian Med Univ, Union Hosp, Dept Thorac Surg, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China
[2] Fujian Med Univ, Key Lab Cardiothorac Surg, Fuzhou, Peoples R China
[3] Fujian Med Univ, Minist Educ Gastrointestinal Canc, Key Lab, Fuzhou, Peoples R China
[4] Fujian Med Univ, Fujian Key Lab Tumor Microbiol, Fuzhou, Peoples R China
关键词
Mixed cure model; Lung adenocarcinoma; Stage IA; Histological subtype; Prognostic analysis; CANCER; MICROPAPILLARY;
D O I
10.1186/s12890-023-02725-9
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background We aimed to investigate the factors influencing the cure, recurrence, and metastasis rates of stage IA lung adenocarcinoma, using a mixed cure model. Methods A total of 1,064 patients who underwent video-assisted thoracoscopic pulmonectomy were included. Variable screening was performed using the random forest algorithm and least absolute shrinkage and selection operator approaches. The mixed cure model was used to identify factors affecting patient cure and survival, and a sequential analysis was performed on 5%, 10%, and 20% of the presentational subtype concurrently. A receiver operating characteristics curve was used to determine the best model and construct a nomogram to predict the cure rate. Results The median follow-up time was 58 (range: 3-115) months. Results from the cure part of the mixed model indicated that the predominant subtype, presentational subtype, and tumor diameter were the main prognostic factors affecting cure rate. Therefore, the nomogram to predict the cure rate was constructed based on these factors. The survival part indicated that the predominant subtype was the only factor that influenced recurrence and metastasis. A sequential analysis of the presentational subtype showed it had no significant effect on survival (P > 0.05). Regardless of the recording mode, no significant improvement was observed in the model's discriminative ability. Only a few postoperative pathological specimens showed lymphovascular invasion (LVI); however, the survival curve suggested a significant effect on patient survival. Conclusions After excluding the existence of long-term survivors, the predominant tumor subtype was determined to be the only factor influencing recurrence and metastasis. Although LVI is rare in stage IA lung adenocarcinoma, its significance cannot be discounted in terms of determining patient prognosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study
    Zhixin Huang
    Dinghang Chen
    Zhinuan Hong
    Mingqiang Kang
    BMC Pulmonary Medicine, 23
  • [2] Segmentectomy Versus Wedge Resection for Stage IA Lung Adenocarcinoma-A Population-Based Study
    Chiang, Xu-Heng
    Wei, Chih-Fu
    Lin, Ching-Chun
    Lin, Mong-Wei
    Chiang, Chun-Ju
    Lee, Wen-Chung
    Chen, Jin-Shing
    Chen, Pau-Chung
    CANCERS, 2025, 17 (06)
  • [3] Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma
    Jeon, Hyun Woo
    Kim, Young-Du
    Sim, Sung Bo
    Moon, Mi Hyoung
    THORACIC CANCER, 2021, 12 (13) : 1952 - 1958
  • [4] Oncologic outcomes of segmentectomy vs lobectomy in pathologic stage IA (≤2 cm) invasive lung adenocarcinoma: A population-based study
    Li, Feng
    Zhao, Yue
    Yuan, Ligong
    Wang, Shuaibo
    Mao, Yousheng
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (07) : 1132 - 1139
  • [5] Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma
    Zhai, Wenyu
    Liang, Dachuan
    Duan, Fangfang
    Wong, Wingshing
    Yan, Qihang
    Gong, Li
    Lai, Renchun
    Dai, Shuqin
    Long, Hao
    Wang, Junye
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [6] Survival analysis and clinicopathological features of patients with stage IA lung adenocarcinoma
    Li, Jiahao
    Wang, Yadong
    Liu, Yong
    Liu, Qiang
    Shen, Hongchang
    Ren, Xiaoyang
    Du, Jiajun
    HELIYON, 2024, 10 (01)
  • [7] Nomogram for predicting recurrence and metastasis of stage IA lung adenocarcinoma treated by videoassisted thoracoscopic lobectomy
    Huang, Zhixin
    Peng, Kaiming
    Hong, Zhinuan
    Zhang, Peipei
    Kang, Mingqiang
    ASIAN JOURNAL OF SURGERY, 2022, 45 (12) : 2691 - 2699
  • [8] A gene-based score for the risk stratification of stage IA lung adenocarcinoma
    Xiong, Yanlu
    Ma, Yongfu
    Liu, Kun
    Lei, Jie
    Zhao, Jinbo
    Zhu, Jianfei
    Wang, Wenchen
    Wen, Miaomiao
    Wang, Xuejiao
    Sun, Ying
    Zhao, Yabo
    Han, Yong
    Jiang, Tao
    Liu, Yang
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [9] Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based study
    Bai, Wenliang
    Zhang, Jiaqi
    Wang, Yanqing
    Zhou, Mengxin
    Liu, Lei
    Wang, Guige
    Zhao, Ke
    Gao, Xuehan
    Li, Shanqing
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (02) : 215 - 228
  • [10] Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma
    Yang, Lu
    Zhang, Jing
    Song, Yane
    Yang, Guangjian
    Xu, Haiyan
    Li, Junling
    Guo, Lei
    Li, Xin
    Shi, Xinying
    Mao, Beibei
    Yang, Ying
    Wu, Lijia
    Wei, Jiyu
    Zhang, Henghui
    Ying, Jianming
    Wang, Yan
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):